1. Home
  2. SBGI vs CMPX Comparison

SBGI vs CMPX Comparison

Compare SBGI & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sinclair Inc.

SBGI

Sinclair Inc.

HOLD

Current Price

$14.97

Market Cap

1.0B

Sector

Industrials

ML Signal

HOLD

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$6.27

Market Cap

926.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBGI
CMPX
Founded
1986
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
926.7M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
SBGI
CMPX
Price
$14.97
$6.27
Analyst Decision
Buy
Strong Buy
Analyst Count
5
11
Target Price
$21.00
$13.44
AVG Volume (30 Days)
362.1K
2.1M
Earning Date
02-25-2026
03-18-2026
Dividend Yield
6.68%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,337,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8.28
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.89
$1.33
52 Week High
$17.88
$6.88

Technical Indicators

Market Signals
Indicator
SBGI
CMPX
Relative Strength Index (RSI) 52.83 54.00
Support Level $14.37 $6.05
Resistance Level $15.30 $6.82
Average True Range (ATR) 0.57 0.38
MACD 0.10 -0.04
Stochastic Oscillator 82.34 26.51

Price Performance

Historical Comparison
SBGI
CMPX

About SBGI Sinclair Inc.

Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.

Share on Social Networks: